Anticoagulation and antiplatelet therapy in patients with prosthetic heart valves.

Joel Aikins, Abeku Koomson, Mofolaoluwami Ladele, Lana Al-Nusair, Amna Ahmed, Amr Ashry, Amer Harky

Journal: Journal of cardiac surgery 2021;35(12):3521-3529

PMID: 32939828

Full Text on Ovid Technologies, Inc. View on PubMed

Abstract

BACKGROUND

The choice of antithrombotic therapy, anticoagulants or antiplatelets, after prosthetic heart valve replacement or repair, remains a disputed topic in the literature. Antithrombotic therapies are used after heart valve intervention to reduce the rates of thromboembolic events, therefore improving patient outcomes. Different interventions may require different therapeutic regimens to achieve the most efficacious clinical outcome for patients.

METHODS AND DISCUSSION

This review aims to summarize and critique the available literature concerning therapeutic agents used for bioprosthetic and mechanical valves as well as for valve repair, so as to assist clinicians and researchers in making decisions with regard to their patients and research endeavors.

Address: Imperial College School of Medicine, Faculty of Medicine, Imperial College London, London, UK.; Department of Cardiothoracic Surgery, Liverpool Heart and Chest, Liverpool, UK.; Department of Cardiothoracic Surgery, Assiut University Hospital, Assiut, Egypt.; Department of Cardiothoracic Surgery, Liverpool Heart and Chest, Liverpool, UK.; Department of Integrative Biology, Faculty of Life Science, University of Liverpool, Liverpool, UK.; Liverpool Centre for Cardiovascular Science, Liverpool Heart and Chest Hospital, Liverpool, UK.

DOI: 10.1111/jocs.15034

Link outs

Subscription / membership required

Full Text Sources:

MeSH Terms: Anticoagulants, Heart Valve Prosthesis, Humans, Platelet Aggregation Inhibitors, Thromboembolism